On 21 October 2024, Novo Nordisk announced positive results from the SOUL cardiovascular outcomes trial, which evaluated the impact of Rybelsus (oral semaglutide) on major adverse cardiovascular events (MACE) in individuals with type 2 diabetes and established cardiovascular disease (CVD) or chronic kidney disease (CKD)
FAQ These FAQs address common questions about Foundayo treatment and help clarify expectations, allowing women to move forward with confidence
Body mass index (BMI) and current tobacco smoking mediated 20.28% and 6.65%, respectively, of the total effect of GLP-1RAs on SA risk
Unlike stimulant-based diet aids, peptides for weight loss in Centennial work harmoniously with your body's own processes, making them a safer, more effective option
When used along with a healthy diet and exercise routine, these medications can help promote and maintain weight loss